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Objective: DNA methylation markers have been assessed as potential biomarkers for early 
cervical cancer detection. Herein, we evaluated the diagnostic performance of zinc finger protein 
582 (ZNF582) methylation for cervical cancer detection. 
Methods: Eligible studies were systematically searched from the electronic databases. The 
quality of enrolled studies was evaluated using the second version of the check list for Quality 
Assessment of Diagnostic Accuracy Studies (QUADAS-2).The bivariate meta-analysis model 
was employed to plot the summary receiver operator characteristic (SROC) curve using Stata 
14.0 software. Cochran’s Q test and I2 statistics were applied to assess heterogeneity among 
studies. Publication bias was evaluated by the Deeks’ funnel plot asymmetry test. 
Results: Seven studies composed of 1749 patients were eventually included. The pooled 
sensitivity of ZNF582 methylation was estimated to be 0.71 [95% confidence interval (CI): 0.67-
0.75] in differentiating patients with cervical intraepithelial neoplasia type III/worse (CIN3+), 
corresponding to a specificity of 0.81 (95% CI: 0.79-0.83) and area under the curve (AUC) of 
0.85. Our stratified analysis suggested that sequential combined of HPV DNA and ZNF582 
methylation test (AUC, sensitivity and specificity of 0.876, 0.75 and 0.87, respectively) achieved 
higher diagnostic accuracy than single HPV DNA testing test (AUC, sensitivity and specificity 
of 0.669, 0.96 and 0.41, respectively).  
Conclusions: ZNF582 methylation has a prospect to be an auxiliary biomarker for cervical 
cancer screening. A new strategy of co-testing HPV DNA and ZNF582 methylation test in 







ZNF582 methylation as a potential biomarker to predict CIN3+: A meta-analysis of related studies in Chinese population 
87 
Introduction 
Cervical cancer is one of the main causes of death of women worldwide 1-3. The most widely 
used screening methods for cervical cancer are the cytology-based Pap smear and high-risk 
human papillomavirus (hrHPV) test. However, cytomorphological examination of cervical 
smears is not ideal because of its relatively low sensitivity 4. Although hrHPV testing improves 
the sensitivity of cervical screening 5, the specificity of hrHPV testing, especially in a young 
screening population, is relatively low 6. Therefore in hrHPV primary screening programs, the 
less specific screening test may lead to substantially heavy burden on health care resources, such 
as unnecessary referral to colposcopy makes triage testing compulsory. In this respect, 
discovering and developing new biomarkers which confer high sensitivity and specificity for 
cervical cancer detection is a matter of great urgency in the clinic. 
Gene silencing by promoter hypermethylation has been shown to contribute to cervical 
carcinogenesis and methylation analysis of cervical-cancer-specific genes has been suggested as 
a valuable, alternative or additive triage tool 7-10. Among these altered and methylated genes, the 
ZNF582 was highlighted 11-16. As reported, ZNF582 is frequently silenced by methylation in 
cervical cancers, and literature have documented the promise of ZNF582 methylation in the 
detection of cervical precancerous lesions 17. In order to make a comparison of the accuracy of 
DNA methylation and HPV DNA testing, we performed a comprehensive meta-analysis and 
evaluated the diagnostic performance of ZNF582 methylation for the detection of cervical 






Search strategy  
This meta-analysis was conducted in compliance with the guidelines of the Preferred Reporting 
Items for Systematic Reviews and Meta-analysis (PRISMA) Statement issued in 2015 18. Three 
electronic databases, Pubmed/Medline, Embase, and Cochrane, were searched for relevant 
studies until March 1 2018, using the following Keywords: (cervical cancer or cervical 
intraepithelial neoplasia or CIN or uterine cervical neoplasm or uterine cervical dysplasia) and 
(methylation marker or methylation or DNA methylation) and (zinc finger protein 582 or 




The references of all publications were hand-searched in order to identify missing relevant 
publications. The following criteria were used for the literature selection in this meta-analysis: (1) 
studies evaluated the diagnostic performance of ZNF582 methylation or HPV DNA testing in the 
diagnosis of high-grade squamous intraepithelial lesion (HSIL) or cervical neoplasms; (2) studies 
explicitly mentioned the sample size, sensitivity, specificity and their 95% confidence intervals 
(CIs) or other more detailed information; (3) Matched controls were included. Literature was 
excluded according to the following criteria: (1) the control group and sample sizes were unclear; 
(2) studies without complete data including missing information of sensitivity, specificity or area 
under the curve (AUC) value, and so on; (3) studies didn’t used histology as gold standard and (4) 
basic research, animal studies, meta-analysis, review articles, letters, commentaries, abstracts 
presented at conferences, and so on.  
 
Data extraction and quality assessment 
All the included studies were carefully reviewed independently by two investigators (Li and He) . 
All analyses were based on previously published studies, thus no ethical approval and patient 
consent are required. Data from these articles were extracted according to a predefined 
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registration form. The following information was extracted: the first author, country, year of 
publication, patient size, study design, CIN degrees, test method and the diagnostic results, 
methylation methods, cut-off value, HPV status. In studies contained both a training and a 
validation group, data from each group was treated as a single study in the meta-analysis. The 
quality of each included study was evaluated using the second version of the check list for 
Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) 19. A score was given to 4 
domains (participant selection, triage test, reference standard, and flow & timing), based on a set 




Statistical analysis was undertaken using Stata 14.0 (Stata Corporation, College Station, TX, 
USA), and Meta-disc 1.4 (XI Cochrane Colloquium, Barcelona, Spain) software. The bivariate 
meta-analysis model was employed to summarize the sensitivity, specificity, diagnostic odds 
ratio (DOR), positive likelihood ratio (PLR) and negative likelihood ratio (NLR) and to generate 
the bivariate summary receiver operator characteristic (SROC) curves with their corresponding 
95% CI. The pooled diagnostic indices were calculated by using a random-effects model 20. 
Heterogeneity from threshold and non-threshold effects were reflected by the Spearman 
correlation coefficient, Cochran’s-Q and I2 tests 21, respectively. Meta-regression and subgroup 
analysis were performed to trace potential sources of study heterogeneity. The covariates 
included the following: age (average age ≤45 or >45), publication year (≤2014 or >2014), sample 
size (≤200 or >200), study location (China or Chinese Taipei). Deeks’ funnel plot asymmetry test 






Study characteristics and quality 
A total of 422 studies were retrieved from a primary literature search in electronic databases, and 
406 studies were excluded due to the status that unrelated to ZNF582 methylation or cervical 
cancer diagnosis. Nine studies were left for full-text evaluation. In 1 study, the clinical accuracy 
calculated only in cervical adenocarcinoma was further excluded 22. Another study didn’t use 
histology as gold standard was discarded as well 23. Seven studies for ZNF582 methylation and 4 
studies for HPV DNA test were included in this meta-analysis. The selection process for relevant 
studies is shown in Figure 1. 
All of the 7 studies were conducted in Asia, including 4 studies in Chinese Taiwan and 3 in 
China mainland. The final diagnoses of all studies were determined by tissue-proven 
histopathology, and the evaluation method for DNA methylation was quantitative methylation-
specific polymerase chain reaction (QMSP). The main features of each included study were 
described in Table 1. We evaluated the study quality of each included publications according to 
the QUADAS2 assessment tool 19. As shown in Figure 2, all of the 7 studies revealed lower risks 









Figure 1. Flowchart of the literature search and study selection procedure. 
 











Figure 2. Summary of assessment of the included studies analyzed using the QUADAS2 tool: studies with low, mediate (unclear), 
and high risk of bias. QUADAS=quality assessment for studies of diagnostic accuracy. 
 
Table 1. The main features of included studies for ZNF582 methylation in diagnosing cervical cancer. 
      Patient size       
Author Year Study location Total CIN3+/cancer Control size HPV type Method Cut-off value 
Liou et al 11 2016  China 449 158 291 ─ QMSP based on ROC 
Chang et al 12 2015 China Taiwan 53 7 46 ─ QMSP based on ROC 
Chang et al 13 2015 China Taiwan 136 66 70 ─ QMSP based on ROC 
Liou et al 16 2015  China 242 74 168 ─ QMSP based on ROC 
Lin et al 14 2014 China Taiwan 230 15 215 ─ QMSP specificity 70% 
Huang et al 15 2012 China Taiwan 327 85 242 ─ QMSP  M-index0.62 
Tian et al 17 2017 China 312 155 157 High risk QMSP ΔCp≦11.0  
HPV =human papillomavirus; QMSP =quantitative methylation-specific polymerase chain reaction. 
 
Table 2. Diagnostic indices of ZNF582 methylation for cervical cancer screening. 
Analysis 
Pooled Sensitivity Pooled Specificity Pooled PLR Pooled NLR Pooled DOR 
AUC (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) 
ZNF582 
0.71 0.81 4.19 0.34 12.72 
0.85 
(0.67-0.75) (0.79-0.83) (3.62-4.85) (0.30-0.39) (9.93-12.68) 
hrHPV 
0.96 0.41 1.69 0.1 18.44 
0.6693 
(0.93-0.98) (0.37-0.45) (1.56-1.83) (0.06-0.18) (9.33-36.47) 
hrHPV/ZNF582 
0.97 0.48 2.45 0.06 31.26 
0.7928 
(0.94-0.99) (0.44-0.52) (2.14-2.80) (0.04-0.12) (15.03-65.03) 
hrHPV and ZNF582 0.75 0.87 5.91 0.34 19.23 0.8762 
  （0.69-0.80） （0.84-0.89） （2.94-11.91） （0.22-0.53） （8.09-45.7）   
No outlier studies identified in ZNF582 methylation test. AUC =area under the curve; CI =confidence interval; DOR =diagnostic 




Heterogeneity from threshold and non-threshold effects were assessed using Meta-disc 1.4 
software. The P-values of spearman correlation coefficient in ZNF582 methylation test, HPV 
DNA test and ZNF582/HPV DNA test were more than 0.05, indicating that there was no 
heterogeneity from threshold effect. For the individual ZNF582 methylation test, the Cochran’s-
Q test yielded a Q value of 7.97 (P >.01), with I2 <50%, suggesting that non-threshold effect is 
not likely to be a source of heterogeneity. However, heterogeneity generated by non-threshold 
effects appeared in the other pooled analyzed with P-values of Cochran’s-Q test less than .01, 
accompanied by I2 >50% (Supplement Digital Content 1, which demonstrates the threshold 
effect analysis, http://links.lww.com/MD/C804). 
 
Diagnostic performance 
As indicated in Table 2, the pooled accuracies for ZNF582 methylation was determined to assess 
their usefulness as a biomarker for screening of patients with CIN3+. The pooled sensitivity, 
specificity, DOR and AUC for ZNF582 methylation test were 0.71 (95% CI: 0.67-0.75), 0.81 (95% 
CI: 0.79-0.83), 12.72 (95% CI: 9.93-12.68) and 0.85, respectively. The forest plots of pooled 
sensitivity, specificity and SROC curves for ZNF582 methylation are displayed in Figures 3 and 
Supplement Digital Content 2, http://links.lww.com/MD/C804. For the HPV DNA testing, it 
yielded an AUC value of 0.669, with pooled sensitivity of 0.96 (95% CI: 0.93-0.98) and 
specificity of 0.41 (95% CI: 0.37-0.45).  
A random effect model was applied in the stratified meta-analyses due to the existence of 
significant heterogeneities among studies. We further validated the diagnostic accuracy of the 
parallel and sequential combinations of ZNF582/HPV DNA test. The results for the stratified 
analyses were listed in Table 2. The paralleled and sequential combinations of ZNF582/HPV 
tests achieved AUC values of 0.793 and 0.876, under which, the pooled sensitivity were 0.97 (95% 
CI: 0.94-0.99) and 0.75 (95% CI: 0.69-0.80), the pooled specificity were 0.48 (95% CI: 0.44-
0.52) and 0.87 (95% CI: 0.84-0.89) respectively. 
 













Figure 3. Forest plots of the pooled sensitivity and specificity for ZNF582 methylation. Only first author of each study was given. 
Sensitivity and specificity were given with CI. CIs =confidence intervals. 
 
Table 3. Meta-regression (inverse variance weights) for the potential source of heterogeneity. 
Stratified Analysis   No. Studies  Sensitivity (95% CI) P1 Specificity (95% CI) P2 
Average age, y      
≤45    4 0.74 (0.66-0.81) .27 0.81 (0.76-0.86) .02 
>45 2 0.72 (0.56-0.87)  0.81 (0.71-0.91)  
Sample size      
≤200 3 0.77 (0.68-0.86) .19 0.79 (0.72-0.87) .00 
>200 3 0.70 (0.62-0.79)  0.82 (0.77-0.87)  
Publication year      
2012-2014 2 0.74 (0.60-0.87) .15 0.77 (0.69-0.84) .00 
2015-2016 4 0.73 (0.66-0.81)  0.83 (0.79-0.88)  
Study location      
China  2 0.73 (0.64-0.82) .07 0.84 (0.79-0.89) .00 
Chinese Taipei 4 0.73 (0.63-0.83)   0.78 (0.72-0.84)   




Influence assay and meta-regression 
We performed influence analysis based on the platform of Stata 14.0 software. No outlier studies 
were identified in ZNF582 methylation test (Supplement Digital Content 3, http://links.lww. 
com/MD/C804). Furthermore, meta-regression and subgroup analyses were conducted by 
assessing the impacts of 4 pre-specified covariates (average age, publication year, sample size, 
study location) on pooled sensitivity and specificity. Our data revealed that these covariates 
introduce heterogeneity in specificity with a P-value less than .05. However these covariates 
showed a low likelihood of sources of inter-study heterogeneity in sensitivity (Table 3, 
Supplement Digital Content 4, http://links.lww.com/MD/C804). 
 
Publication bias 
The funnel plots for publication bias showed no asymmetry for the pooled ZNF582 methylation 
analysis. The slope of coefficient was associated with a P-value of .36, implying that no 
publication bias existed in the studies (Supplement Digital Content 5A, http://links.lww.com/ 
MD/C804). For single HPV DNA test (Supplement Digital Content 5B, http://links.lww.com 
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Discussion 
Because CIN is a dynamic process, the approximate regression rates for CIN I, CIN II, and CIN 
III are 60%, 40%, and 33%, respectively, and their corresponding rates of progression to invasive 
cervical cancer are 1%, 5%, and 12%, respectively 24. Therefore, early diagnosis and treatment of 
CIN can reduce cancer mortality rate through effective screening programs drastically. 
Papanicolaou cytology screening programs detect most CIN with a potential to transform into 
malignancy and for which treatment may prevent the cancer. Unfortunately, the cytology test is 
difficult to implement and retain at high quality, especially in underdeveloped countries 25. The 
sensitivity of HPV DNA testing is satisfactory, whereas the high prevalence of transient HPV 
infections had limited the specificity of this approach 26, 27 .Of greater importance are accurate 
molecular prognostic classifiers which could be done on the screening specimen and would 
reflexively indicate the future risk of progression. The ability to accurately tell whether the HPV 
infection will become a CIN3 or disappear would radically trans-form screening programs. The 
results would be reduced testing, lower costs, fewer overtreatments and less anxiety28 . 
ZNF582, located at chromosome 19q13.43, encodes the Krüppel-type zinc finger protein 582 
(HGNC: 26421), which contains 1 KRAB-A-B domain and nine zinc-finger motifs 29. However, 
the biological function of ZNF582 is not yet well characterized. Most KRAB-ZNF proteins 
contain the KRAB (AB) domain and bind KRAB-associated protein 1 (KAP1) to co-repress gene 
transcription 30, 31. Members of the KRAB-ZNF family are probably involved in a variety of 
biological processes related to the DNA damage response, proliferation, cell cycle control, and 
neoplastic transformation 30. Recent studies revealed that methylation of its promotor CpG island 
is an important regulating manner in epigenetics, which is closed related to the development of 
malignant tumor, such as oral cancer 32, 33, esophageal squamous cell carcinoma 34, colorectal 
cancer 35 and leukemia 36 .  
In the development of cervical cancer, ZNF582 is silenced by hypermethylation, hence the 
methylation of ZNF582 has been proposed as a potential biomarker for the detection of cervical 
cancer 23. As the potential diagnostic value of DNA methylation for cervical cancer screening 
has not yet been well elucidated thus far, we performed a comprehensive meta-analysis and 
evaluated the diagnostic performance of ZNF582 methylation for the detection CIN3+. And we 
also evaluated the pooled diagnostic accuracy of HPV DNA test from the published studies. As 
Chapter 4 
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shown in our data, the pooled sensitivity and specificity of ZNF582 methylation was 0.71 and 
0.81, respectively. Although the pooled sensitivity appeared not very high, the ROC AUC was 
0.85, suggesting an overall high accuracy of this diagnostic test. DOR is one of the key 
indicators in assessing the accuracy of 1 diagnostic test, and that a DOR smaller than 1.0 often 
suggests a low discriminating value for a diagnostic test 37, 38 . Importantly, the pooled DOR for 
ZNF582 methylation was 12.72, indicating a better discriminatory test performance of ZNF582 
methylation for CIN3+ detection. Moreover, the pooled PLR of 4.19, also suggested that patients 
with CIN3+ had nearly 4 fold higher chance of being ZNF582 methylation test positive than 
individuals without CIN3+. A pooled NLR of 0.34 means that the probability of the individuals 
having CIN3+ is 34% when the ZNF582 test is negative. HPV DNA test harbored much high 
pooled sensitivity for the detection of CIN3+, but with much lower specificity with AUC of 
0.669. Our data provide evidence that ZNF582 methylation confers better diagnostic accuracy in 
detecting CIN3+.  
We further conducted the stratified analyses to compare the diagnostic accuracy of ZNF582 
methylation and HPV DNA test. Combined sequential testing of HPV DNA and ZNF582 
methylation achieved an improved diagnostic accuracy compared to HPV DNA test alone with 
AUC and DOR of 0.876 and 19.23. 
In this study, heterogeneity from non-threshold effects existed in the pooled studies. It is 
speculated that sample size, age and study location may contribute to the heterogeneity sources. 
We further conducted influence and meta-regression analyses and our results revealed that the 
study location and sample size were likely to be a source of heterogeneity. 
Although we did our best to conduct a comprehensive analysis, some limitations still exist. Only 
7 studies were include in this meta-analysis, and all the studies included in this meta-analysis 
were conducted in Chinese Taipei and China. The results of this analysis in Chinese populations 
should be applicable to other developing countries with high incidence of CIN. 
In conclusion, our meta-analysis revealed that ZNF582 achieves a promising diagnostic 
performance for CIN3+. And combined sequential HPV DNA and ZNF582 methylation test 
achieves an improved diagnostic accuracy compared to HPV DNA test alone. Therefore, we 
suggest that ZNF582 methylation assay can be used as an auxiliary biomarker for cervical cancer 
screening. Further high quality studies from other geographies are still warranted to confirm our 
analyses. 
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Supplement Digital Content 1. Heterogeneity analysis of the pooled studies using meta-disc 1.4 software. 













a 7.97b 24.7 No No 
P=0.357 P=0.2405    
hrHPV 0.4
a 20.48b 85.4 No Yes 
P=0.6 P=0.0001    
hrHPV/ZNF582 0.000
a 34.5b 91.3 No Yes 
P=1 P=0.000    
hrHPV and ZNF582  
0.4a 10.28b 70.8 No Yes 
P=0.6 P=0.0163       






























Supplement Digital Content 2. SROC curve of the pooled ZNF582 methylation tests. Sample size is indicated by the size of the 

















































Supplement Digital Content 5. Funnel graph for the assessment of potential publication bias of the included studies. (A) Deeks’ 
funnel plot asymmetry test for ZNF582 methylation; (B) Deeks’ funnel plot asymmetry test for hrHPV. 
